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Summary 2-(4-Aminophenyl)benzothiazole molecules substituted in the 3 position of the phenyl ring with a halogen atom or methyl moiety
comprise a group of compounds that potently inhibit specific human ovarian carcinoma cell lines. G150 values fall within the nm range. Inhibition
is highly selective - whereas the G150 value in IGROV1 cells consistently lies at < 10 nM, SK-OV-3 presents G150 values > 10jIM. Biphasic
dose-response relationships were observed in sensitive cell lines after 48-h drug exposure. COMPARE analyses revealed the very similar
profiles of anti-tumour activity of 3-substituted benzothiazoles and 5-(4-dimethylaminophenylazo)quinoline, with Pearson correlation coefficients
> 0.65. Anti-tumour activity extended to preliminary in vivo tests. The growth of OVCAR-3 cells in polyvinylidene fluoride (PVDF) hollow fibres
implanted in the peritoneal cavity of mice was inhibited by more than 50% after intraperitoneal (i.p.) administration of 2-(4-amino-3-
methylphenyl)benzothiazole (10 mg kg-'), 2-(4-amino-3-chlorophenyl)benzothiazole (100 mg kg-') or 2-(4-amino-3-bromophenyl)benzothiazole
(150 mg kg-1). The growth of OVCAR-3 tumours in subcutaneously (s.c.) implanted hollow fibres was retarded by more than 50% aftertreatment
with 2-(4-amino-3-methylphenyl)benzothiazole (6.7 and 10 mg kg-1). In addition, the growth of s.c. OVCAR-3 xenografts was delayed after
exposure to DF 203. However, the relationship between drug concentration and growth inhibition was inverse.
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2-(4-Aminophenyl)benzothiazole (CJM 126, Figure 1) was origi-
nally prepared as a synthetic intermediate within a programme to
design potential tyrosine kinase inhibitors modelled on structural
comparisons with the flavone quercetin and isoflavone genistein
(Yates et al, 1991; Stevens et al, 1994). It was found to elicit potent
inhibitory effects against breast cancer cell lines in vitro, yielding
biphasic dose-response profiles (Shi et al, 1996). Numerous
analogues were synthesized and their biological activity exam-
ined. Replacement ofthe sulphur atom in the heterocyclic nucleus
to generate benzoxazole or benzimidazole congeners had a
dyschemotherapeutic effect. In contrast, substitution at position 3
of the phenyl ring with a halogen atom or a methyl group signifi-
cantly enhanced potency (Shi et al, 1996). GI50 values within the
pM range were obtained in human breast carcinoma cell lines
including MCF-7 oestrogen receptor-positive (ER+) and MDA
468 oestrogen receptor-negative (ER-) cell lines. In contrast, GI50
values > 30 gm were obtained when activity of the same
compounds was examined in PC3 and DU 145 human prostate cell
lines (Bradshaw et al, 1998).
Anti-tumour activity extended to breast xenograft models with
ER+ (MCF-7 and BO) and ER- (MT-1, MT-3 and MaTu) human
tumours grown in nude mice responding to treatment with
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2-(4-amino-3-methylphenyl)benzothiazole, as well as 2-(4-amino-
3-iodophenyl)benzothiazole retarding the growth of MCF-7, 3366
(ER+) and MaTu (ER-) tumour xenografts (Shi et al, 1996).
Such promising preliminary results led to wider investigations
and compounds were forwarded to the National Cancer Institute,
where a more comprehensive anti-tumour evaluation proceeded.
-In this paper, we describe the effects ofbenzothiazole molecules
on human ovarian tumour growth in vitro and in vivo and 5-(4-
dimethylaminophenylazo)quinoline on human ovarian tumour
growth in vitro. The order ofbenzothiazole molecules discussed is
as follows: unsubstituted 2-(4-aminophenyl)benzothiazole (CJM
126); molecules substituted with a halogen species at position 3 of
the phenyl ring (DF 129, DF 209, DF 229); methyl substituted
benzothiazole (DF 203); and further analogues in ascending DF
numerical sequence (DF 180, DF 219, DF 221, DF 226).
MATERIALS AND METHODS
Drugs
2-(4-Aminophenyl)benzothiazole (CJM 126), 2-(4-amino-3-
iodophenyl)benzothiazole (DF 129), 2-(4-amino-3-bromophenyl)
benzothiazole (DF 209), 2-(4-amino-3-chlorophenyl)benzo-
thiazole (DF 229), 2-(4-amino-3-methylphenyl)benzothiazole (DF
203), 2-(N-chloroacetylaminophenyl)benzothiazole (DF 180),
2-(4-amino-3-iodophenyl)-6-methylbenzothiazole (DF 219), 2-
(4-amino-3,5-dibromophenyl)benzothiazole (DF 221) and 2-
(4-amino-3,5-dichlorophenyl)benzothiazole (DF 226) were
synthesized according to published methods (Shi et al, 1996).
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Ovarian cell lines and in vitro evaluation of growth
inhibitory effects
The activity of CJM 126, DF 129, DF 209, DF 229, DF 203, DF
180, DF 219, DF 221, DF 226 and NSC 680467 was examined in
six ovarian cell lines (IGROV1, OVCAR-3, OVCAR-4, OVCAR-5,
OVCAR-8 and SK-OV-3) in the laboratories of the NCI, Bethesda,
MD, USA. The protocol adopted has been described in detail previ-
ously (Boyd, 1989; Monks etal, 1991, 1997). After initial drug incu-
bation periods of48 h, cell growth or viability was assayed using the
sulphorhodamine B procedure. The change in protein stain optical
density allows a concentration-effect curve for the inhibition ofcell
growth to be constructed. Compounds were tested between two and
four times following this procedure; subsequently, 6-day drug incu-
bations (DF 129, DF 209, DF 229 and DF 203) preceded analysis of
cell growth or viability in four ovarian lines.
Two ovarian tumour cell lines were developed within the
Department of Oncology, Derby City General Hospital, Derby,
UK, from a solid tumour (D13) and ascites (OAW 42) (Wilson,
1984) ofpatients with a diagnosis of ovarian carcinoma. OAW 42
and Dl3 ovarian cancer cell lines were plated onto 96-well plates
at densities of 1.5 x 103 and 9 x 103 per well respectively. After
overnight drug-free incubation, DF 129, DF 229, DF 203 and DF
180 were added at four tenfold dilutions starting at a maximum
concentration of 104 M. Each drug was assayed two to three times.
After a 72-h exposure, cells were rinsed twice with 200 jl of
phosphate-buffered saline (PBS) and fixed for 10 min with 10%
formalin in 200 gl of PBS. They were then washed twice with
200gl of 0.01 M borate solution and stained for 10 min with 1%
methylene blue in 0.01 M borate (100 gl). Plates were dried and
dye-solubilized with 200 ,l of0.1 Nhydrochloric acid. Plates were
read at 650 nm on a UV max plate reader and GI50 values calcu-
lated from the dose-response curves.
The activity ofbenzothiazole molecules was tested against seven
human ovarian cell lines at the Institute of Cancer Research,
Sutton, Surrey, UK. The following cell lines were recruited for
study: A2780 and its cisplatin-resistant variant A2780cisR (resis-
tance factor 15.7); CHI and its cisplatin-resistant variant CHlcisR
(resistance factor 7.0); IGROV1-ICR; OVCAR-3-ICR; and SK-
OV-3-ICR. Seeding densities varied according to growth character-
istics. Test compounds were added at five tenfold dilutions starting
at a maximum of 10-4M. After a 96-h exposure, growth and
viability was assessed using the sulphorhodamine B assay. Mean
values from two to three independent experiments were calculated.
Clonogenic assays were performed at the Experimental
Oncology Institute, University of Freiburg, Germany, on tumour
cells derived from three human ovarian xenografts: 899, 1023 and
1353. Solid human tumour xenografts growing subcutaneously in
NMRI nu/nu mice were removed under sterile conditions. After
mechanical disaggregation, specimens were incubated with an
enzyme cocktail consisting of collagenase (1.2 U ml-',
Worthington), DNAase (375 U ml-', Boehringer Mannheim) and
hyaluronidase (29 U ml-', Boehringer Mannheim) in RPMI 1640
at 37°C for 30 min. Cells were washed twice with PBS and passed
through 200-,im, and 50-,um mesh sieves. Viable cells were deter-
mined using trypan blue exclusion. Clonogenic assays were
performed according to a modified two-layer soft-agar protocol
(Hamburger and Salmon, 1977). Initial seeding densities were
2.5 x 105per ml for 1023 cells and 3 x 105per ml for 899 and 1353
cells. CJM 126, DF 129, DF 203 and DF 180 exposure was contin-
uous (n = 3, control n = 6). Drug-treated 1023, 899 and 1353
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Figure 1 Structures of 2-(4-aminophenyl)benzothiazoles and 5-(4-
dimethylaminophenylazo)quinoline (NSC 680467)
cultures were incubated for 7, 8 and 9 days respectively. Colony
growth was monitored using an inverted microscope. Counts were
performed using an automatic image analysis system (OMNICON
FAS IV, Biosys). Inhibition of colony formation was represented
as the ratio oftreated to control colony number (% T/C), and drug
concentrations necessary to inhibit colony formation by 50%
(GI50, T/C 50%), 70% (GI70, T/C 30%) and 90% (GI90, T/C 10%)
were determined. Assays were considered evaluable if: the
mean number of colonies (diameter > 50 jim) was 20 or more;
1000 jig ml-' 5-fluorouracil (5-FU) (positive reference compound)
effected colony survival by < 30%; and the coefficient ofvariation
in the control group was < 50%.
COMPARE analysis
COMPARE is the computerized pattern-recognition algorithm
used in evaluation of data generated by the NCI screen. It is a
method of determining and expressing the degree of similarity, or
lack thereof, ofmean graph profiles generated on compounds. The
response profile fingerprints of DF 129, DF 209, DF 229, DF 203
and NSC 680467 were used as 'seeds' to probe other mean graph
databases to examine whether any closely matching profiles exist.
Compounds matched by mean graph patterns frequently share
related biochemical mechanisms ofaction (Weinstein et al, 1997).
In vivo evaluation of activity
The Biological Testing Branch ofthe Developmental Therapeutics
Program (NCI) has adopted the hollow-fibre assay as a preliminary
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Table 1 Inhibition of growth of NCI human-derived ovarian cell lines in vitro by benzothiazole molecules
Mean Gl5s (gM)
CJM DF 129 DF 129 DF 209 DF 209 DF 229 DF 229 DF 203 DF 203 DF 180 DF 219 DF 221 DF 226 NSC
126 (6 days) (6 days) (6 days) (6 days) 680467
IGROV1 59.2 < 0.01a < 0.01 < 0.01a < 0.01a < 0.01a < 0.01 0.04a < 0.01 1.82 0.82a 5.12 0.33a 0.02a
OVCAR-3 58.0 < 0.01a < 0.01a 0.10a 1.86 40.0 > 100 > 100 22.9
OVCAR-4 52.3 0.05a 0.43a 1.00a 0.55 2.82 2.08 6.56a 0.97a > 100
OVCAR-5 52.0 0.30a 0.02a 0.37a < 0.01a 0.04a < 0.01a 0.77a < 0.01a 2.04 59.6 > 100 1.82a 0.68a
OVCAR-8 > 100 > 100 95.4 56.8 43.6 > 100 28.8 > 100 27.5 1.82 84.3 > 100 > 100 > 100
SK-OV-3 69.2 50.9 56.2 > 100 58.9 > 100 81.3 > 100 6.31 62.8 > 100 > 100 > 100
aBiphasic dose-response relationship. Representative GI50 values are given. Compounds were tested by the NCI between two and four times after 48-h
exposure (6 day incubations are indicated).
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Figure 2 Effects of 48-h exposure of DF 129, DF 209, DF 229, DF 203 and NSC 680467 on the growth and viability of IGROV1, OVCAR-5 and OVCAR-8 NCI
human ovarian cell lines in vitro. Mean values from representative experiments are illustrated. Agents were tested two to four times
in vivo screening tool for assessing the potential anti-cancer (PVDF) hollow fibres. A sample of each cell line was implanted
activity of compounds identified by the in vitro cell screen. subcutaneously (s.c.) and intraperitoneally (i.p.) into pathogen-free
OVCAR-3 and OVCAR-5 human ovarian cells were 2 of 12 human immunodeficient athymic female nude mice. Each test mouse
tumour cell lines of different origin (including lung, melanoma, received six fibres (three i.p. and three s.c.) representing three
CNS and colon, for example) cultivated in polyvinylidene fluoride distinct cancer cell lines. Three mice were treated i.p. with test
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Figure 3 Effect of DF 129, DF 209, DF 229 and DF 203 on growth of human-derived NCI ovarian cell lines. IGROVI, OVCAR-5 and OVCAR-8 cells were
exposed for 6 days to benzothiazoles. Mean values from representative experiments are illustrated
compound (two doses) daily for 4 days. Six control mice received
compound vehicle only. The fibre cultures were collected 24 h after
the final treatment. Viable cell mass was determined using the
formazan dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) conversion assay and the ratio oftreated to
control tumour volumes (% T/C) calculated.
The response of early-stage s.c. OVCAR-3 ovarian tumour
xenografts to DF 203 was examined by the NCI after selection
of this compound for further study in the Developmental
Therapeutics Programme. Tumour in the form of cell suspension
was implanted s.c. into pathogen-free immunodeficient athymic
female nude mice on experimental day 0. In addition to control
and test agent-treated groups (n = 6), titration groups were
included to establish tumour doubling time. A total of three treat-
ments were administered i.p. on days 8, 12 and 16. Vehicle was
0.1 ml per 10 g of body weight saline plus Tween 80, 0.05%;
control animals received 10% dimethyl sulphoxide (DMSO) plus
saline. Growth delay was determined and expressed as a
percentage by which the treated-group median weight was delayed
in achieving 1 g compared with that of controls.
RESULTS
In vitro evaluation of anti-tumour activity
CJM 126 was inactive in the NCI ovarian panel. GI50 values
> 50 gM were obtained (Table 1).
Potent yet highly selective inhibition of ovarian cell lines was
observed after a48-h exposure to DF 129, DF 209, DF 229 and DF
203 (Figure 2). Whereas IGROVI, OVCAR-3 or OVCAR-5 were
sensitive, OVCAR-8 or SK-OV-3 cell lines were universally resis-
tant to the growth-inhibitory properties of these compounds. GI50
values beyond the concentration range adopted by the NCI were
seen: < 10 nm for IGROVI and > 100 gM for SK-OV-3 cultures
after exposure to DF 209 or DF 229, a differential greater than four
orders of magnitude (Table 1). Indeed, GI90 values < 10 nm were
obtained in the IGROVI cell line (n = 3) and, at concentrations of
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Figure 4 Profile of anti-tumour activity of DF 129, DF 209, DF 229 and DF
203 in the NCI ovarian cell line panel after 6-day exposure. Sensitivity is
indicated by deviation to the right from log10 mid-GI50 values calculated from
the whole tumour panel of 60 human-derived cell lines. GI50 values for each
ovarian cell line are given in Table 1
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Figure 5 Effect of DF 180 on growth and viability of NCI human ovarian cell
lines in vitro. Mean values from representative experiments are illustrated.
DF 180 was tested three times
100 nM and 1 gM, cell numbers were significantly below initial
seeding density. Unusually, biphasic dose-response relationships
were seen in IGROVI, OVCAR-5 (Figure 2) OVCAR-3 and
OVCAR-4 sensitive ovarian cell lines. Higher potency was
achieved in wells treated with 100 nm or 1 gM DF 129, DF 209,
DF 229 or DF 203 compared with 10gM or 100 ,UM exposure.
DF 203 appeared to be the least potent of the four 3-substituted
benzothiazole molecules in vitro. Although GI50 values fell within
the nm range in IGROV-1, OVCAR-3, OVCAR-4 and OVCAR-5
cell lines, cell numbers after 48 h oftreatment exceeded the initial
seeding density at all concentrations examined.
Anti-tumour activity in IGROV1, OVCAR-5, OVCAR-8 (DF
203) and SK-OV-3 (DF 129, DF 209 and DF 229) cell lines was
assessed after 6-day exposure (Table 1). Benzothiazole-insensitive
OVCAR-8 and SK-OV-3 cell lines yielded GI50 values >10,IM.
Powerful inhibition of IGROV1 growth was observed: IC 9 values
< 10 nm were encountered with DF 129, DF 209 and DF 229. The
Table 2 Effect of benzothiazole molecules on growth of human-derived
ovarian cells in vitro
MeanG150(gIM)
CJM 126 DF 129 DF 209 DF 229 DF 203 DF 180
OAW 42a 0.19 < 0.10 1.23 14.05
D13 > 100 60 > 100 20.50
A2780 > 100 > 100 > 100 1.25
A2780 cisR 41.00 > 100 18.00 1.60
CH1 24.50 35.20 41.70 17.80 1.65
CH1cisR 83.00 94.00 42.00 2.65
SK-OV-3-ICR > 100 > 100 > 100 4.40
OVCAR-3-ICR 86.00 64.00 > 100 76.00
IGROV1-ICR 48.00 0.02 < 0.01 34.00
899 > 44.25 0.19b > 41.61b > 33.06
1023 > 44.25 0.18b > 41.61 9.46
1353 > 44.25 > 28.42b 0.38b 18.59
aMean GI50 values of two experiments: intraexperimental standard deviations
< 16% for DF 180; < 7.4% for DF 129; < 5.2% for DF 203. For DF 229,
representative GI5 values of one of three experiments are shown. bBiphasic
dose-response relationship.
Table 3 The computerized pattern-recognition algorithm after analyses of
the profiles of anti-tumour activity of benzothiazoles and NSC 680467
Pearson correlation coefficient
Seed DF 129 DF 209 DF 229 DF 203 NSC 680467
DF 129 1.00 0.803 0.757 0.796 NDB
DF 209 0.816 1.00 0.957 0.673 0.689
DF 229 0.747 0.957 1.00 0.654 0.705
DF 203 0.796 0.734 0.697 1.00 NDB
NSC 680467 0.678 0.722 0.681 0.872 1.00
NDB indicates compound was not in the database at time of analysis.
Table 4 Effect of benzothiazole molecules on growth of NCI ovarian cell
lines in PVDF hollow fibres in vivo
% T/C
OVCAR-3 OVCAR-5
i.p. s.c. i.p. s.c.
DF 209 (mg kg-')
100 73 > 100 82 90
150 35 > 100 80 > 100
DF 229 (mg kg-')
100 45 76 75 > 100
150 78 80 64 96
DF 203 (mg kg-')
6.7 51 46 50 67
10 46 45 23 67
DF 180 (mg kg-')
100 99 > 100 > 100 63
150 > 100 97 >100 > 100
OVCAR-3 and OVCAR-5 ovarian tumour cells were grown in PVDF hollow
fibres implanted s.c. or i.p. into mice. Three mice received two concentrations
of test compound i.p. (QD x 4 schedule). Six control animals received vehicle
only. Mean tumour cell mass is represented as percentage control growth.
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and DF 180 on the growth of colonies of tumour cells derived from three human ovarian xenografts.
growth potential associated with48-h exposure to 10gM and 100gM
drug (Figure 2) was essentially abolished after 6-day incubations
(Figure 3). In OVCAR-5 populations, potency was significantly
enhanced and GI50 values < 10 nm were obtained after 6-day treat-
ment with DF209 andDF229. However, thebiphasic trendpersisted
atnd was particularly evident after challenge with DF 129 and
DF 203. Figure 4 illustrates clearly the selective nature of growth
inhibition within the ovarian subpanel.
Introduction of a methyl group at position 6 of the benzothia-
zole ring ofDF 129 (DF219) and dibromo or dichloro substitution
in position 3 and 5 ofthe phenyl ring to give DF 221 and DF 226
resulted in diminished potency and reduced cell line selectivity
(Table 1). Biphasic responses were still encountered but shifted
such that the cell nadir occurred at 10gM.
Consistent potency against the NCI ovarian panel was seen after
challenge for 48 h with DF 180. Low ,UM GI50 values were deter-
mined (Table 1). Steep gradients representing fall in cell viabilities
were seen between concentrations differing by only one order of
magnitude: for example, growth of OVCAR-3 cells treated with
1 ,UM DF 180 was 87% that of control, yet 10 JM not only
completely inhibited cell growth but reduced viable cell number to
58% that of initial seeding density (Figure 2).
The selectivity associated with DF 129-, DF 209-, DF 229- and
DF 203-induced growth inhibition compared with the general
toxic nature ofDF 180 has been confirmed in otherhuman-derived
ovarian cell lines (Table 2).
The cell line OAW 42 was at least 540, 280 and 80 times more
sensitive than D13 to DF 129, DF 229 and DF 203 respectively.
DF 229 was the most potent agent, eliciting GI50 values < 0.1JIM
(Table 2). The A431 human epidermoid cell line was used as a
reference line for epidermal growth factor (EGF)-related tyrosine
kinase activity and gave GI50 values > 24 JM in response to
challenge with DF 229 (result not shown).
A2780, A2780cisR, CHl, CHlcisR and SK-OV-3-ICR cells were
not sensitive to the growth-inhibitory properties of CJM 126, DF
129, DF 209 or DF 203 (GI50> 15 JM). The GI50 values of DF 129
and DF 203 were lower in A2780cisR than in the cisplatin-sensitive
parent cell line (2.4- to 5.5-fold respectively). This unusual
British Journal ofCancer(1998) 78(4), 421-429
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Figure 7 Effect of DF 203 (administered i.p.) on early-stage s.c. OVCAR-3
tumour xenograft growth (n = 6)
property was also noted in corresponding cisplatin-sensitive and
resistant lung cell lines (P Twentyman, personal communication).
However, opposing these observations, GI50 values of0.93 and 27.3
,UM were obtained when OAW 42 and D13 cells, respectively, were
treated with cisplatin (data not shown). As noted, OAW 42 cells
displayed the greater sensitivity to DF 129, DF 229 and DF 203
(Table 2). A2780, A2780cisR, CHI, CHlcisR and SK-OV-3-ICR cell
lines were challenged with DF 180, which again proved to be more
potent, yielding GI90 values between 1.25 and 4.4,M (Table 2).
In contrast to data produced at the NCI, OVCAR-3-ICR cells
were insensitive to CJM 126, DF 129, DF 209 and DF 203; GI50
> 40,M were obtained (Table 2). Consistent with results obtained
at the NCI, IGROV1-ICR cells failed to respond to CJM 126 (GI50
48 gM), but were highly sensitive to DF 129 (GI50 23 nM) and DF
209 (GI50 9 nM). However, whereas DF 203 inhibited the growth of
NCI IGROVI cells (GI50 43 nM), the IGROV1-ICR cell line was
refractive to growth inhibition and revealed a GI50 value of34gM.
Colony formation of xenograft 1023 ovarian cells exposed to
0.44gM (100 ng ml-') CJM 126 was inhibited by 24%, whereas
4.42 tM inhibited clonal growth by only 8% (GI50 > 44.25 gM,
Figure 6), revealing the single biphasic growth-inhibitory profile
obtained after treatment with this agent. The growth of 899 and
1353 cells appeared slightly stimulated in response to CJM 126
treatment.
DF 129 induced biphasic responses in each of these three
ovarian xenograft models tested in vitro. GI50 values are given for
899 and 1023 clonal growth of 0.19 and 0.18 gM respectively
(Table 2). However, GI70 andGI90 values were > 28.42 tM. Growth
of 1353 colonies also revealed a biphasic relationship after chal-
lenge with DF 129, yet GI50, GI70 and GI90 values all exceeded
28.42 gM (Figure 6).
After exposure to DF 203, 1353 cells were most responsive,
yielding a biphasic clonal growth curve with GI50 values < 0.42gM
and > 41.6gM. GI50 values were not reached (> 41.6gM) after
treatment of 899 and 1023 cells with DF 203 but a biphasic trend
was seen in the 899 model (Figure 6).
DF 180 caused negligible inhibition of clonogenic growth at
concentrations < 3.31 gM. A sharp decline in viability was
subsequently observed between concentrations of 3.31 gM and
33.06 gM in 1023 and 1353 tumour cells (Figure 6).
COMPARE analysis
DF 129, DF 209, DF 229 and DF 203 were seeded in the NCI
COMPARE programme: benzothiazole molecules substituted in
position 3 of the phenyl ring with a halogen species or methyl
group were COMPARE negative with all known classes ofclinical
agent. High Pearson correlation coefficients (> 0.65) revealed
positive COMPARE analyses between benzothiazoles.
Additionally, compound NSC 680467, 5-(4-dimethylamino-
phenylazo)quinoline (Figure 1) revealed correlation coefficients
> 0.68. As seed compound, NSC 680467 was COMPARE positive
only with the benzothiazoles DF 129, DF 209, DF 229 and DF 203
(Table 3).
A similar profile of anti-tumour activity was demonstrated for
NSC 680467 after 48-h incubation, which reflected the selectivity
exhibited by substituted benzothiazoles (Table 1). Biphasic
dose-response relationships were seen in sensitive IGROV1 cells
(GI50 15 nM) and OVCAR-5 cells (GI50 0.68 gM), but cell numbers
did not descend below the initial seeding densities. OVCAR-8 cells
were refractory to growth inhibition (GI50> 100gM) (Figure 2).
In vivo assessment of ovarian anti-tumour activity
Hollow-fibre assays
DF 209 Whereas % T/C exceeded 100% in OVCAR-3 cells
implanted s.c., exposed to DF 209, i.p. implanted tumour cells
responded to treatment. Inhibition was dose dependent: 27% and
65% reduction in tumour cell mass followed treatment with 100 and
150 mg kg-' respectively. Similarly, only the growth of OVCAR-5
cells implanted i.p. was retarded (150 mg kg-') (Table 4).
DF 229 Significant growth retardation of OVCAR-3 cultures
within the peritoneum was seen (55%) after treatment with
100 mg kg-'. However, the higher dose of 150 mg kg-' induced
only 22% inhibition. OVCAR-3 cells implanted s.c. were inhibited
by 24% and 20% by 100 and 150 mg kg-' DF 229 respectively
(Table 4). Injection of DF 229 had negligible effect on the growth
of OVCAR-5 tumour cells implanted s.c. The growth of tumour
cells implanted i.p. was inhibited by 25% and 36% after treatment
with 100 and 150 mg kg-' respectively.
DF203 In the hollow-fibre in vivo model, DF 203 was the most
effective ofthe benzothiazole anti-tumour agents tested to date. At
concentrations of 6.7 and 10 mg kg-', significant inhibition of
OVCAR-3 cell growth was observed at both tumour implantation
sites: 45 < % T/C < 51. Inhibition of i.p. implanted OVCAR-5
cells exceeded growth inhibition at s.c. sites, with 50% and
77% inhibition of i.p. tumour growth after treatment with 6.7 and
10 mg kg-' DF 203 respectively (Table 4).
Growth inhibition of s.c. OVCAR-3 xenograft tumours was
detected after i.p. administration of 11.2, 16.8 and 25 mg kg-' DF
203. However, only at the lowest dose was % T/C < 50% (Figure
7). The relationship between growth delay and DF 203 concentra-
tion was inverse. The initial mean doubling time of control
tumours was 2.9 days. A maximum-tolerated dose was not
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reached. It was concluded that, on the treatment schedule
evaluated, DF 203 did not have significant anti-tumour activity.
DF 180 DF 180 was essentially inactive against OVCAR-3 and
OVCAR-5 cells cultured in vivo. Only at 100 mg kg-' was the
growth of subcutaneously implanted OVCAR-5 impaired (37%);
however, at the dose of 150 mg kg-', OVCAR-5 growth exceeded
control tumour growth (Table 4).
DISCUSSION
Novel compounds have been synthesized that demonstrated highly
potent anti-tumour activity in specific ovarian (Tables I and 2) in
addition to breast (Shi et al, 1996) cancer cell lines in vitro. An
unusual feature of the dose-response relationship is the biphasic
nature after 48-h DF 129, DF 209, DF 229 and DF 203 exposure.
Initially, cell growth and viability decreased with increasing agent
concentration (10 nM-1 gM). However, at concentrations of 10 and
100 gM, increased viability was encountered. These data are
consistent with biphasic dose-response relationships observed in
benzothiazole-sensitive breast cancer cell lines in which prolifera-
tion associated with DF 129, DF 209, DF 229 and DF 203 concen-
trations . 3 gm was rapidly abolished after extended exposure
periods (Bradshaw et al, 1998). The transient nature of the non-
monotonic dose response was corroborated by 6-day assays
performed by the NCI. Biphasic trends were abrogated in
IGROVl cultures after 6-day exposures to DF 129, DF 209, DF
229 or DF 203. However, evidence of the biphasic nature of the
dose response persisted in OVCAR-5 cells.
The distinct profile of activity elicited by benzothiazoles
compared with no other class of clinical agent. The biological
target of these agents is unknown. DF 129, DF 209, DF 229 and
DF 203 gave near identical activity fingerprints with high (>0.65)
Pearson correlation coefficients, indicating a shared biochemical
mechanism(s) of action (Weinstein et al, 1997). The azoquinoline
NSC 680467 was identified and subsequently evaluated in the
COMPARE programme: only significant correlations were found
with 3-phenyl-substituted benzothiazoles DF 129, DF 209, DF 229
and DF 203. The profile of activity of NSC 680467 in the NCI
ovarian panel partly mimicked those ofthe benzothiazoles. As for
the benzothiazoles, the mechanism ofaction ofNSC 680467 is not
known. Two MCF-7 human breast carcinoma cell lines possessing
acquired resistance to CJM 126 after long-term exposure to this
compound demonstrated a high degree ofcross-resistance not only
to benzothiazoles but also to NSC 680467, yet retained sensitivity
to standard chemotherapeutic agents, such as doxorubicin, tamox-
ifen, mitomycin C and actinomycin D (Bradshaw et al, 1998).
Therefore, a shared mechanism(s) ofresistance is implied.
We have observed rapid uptake and metabolism of benzothia-
zoles by sensitive cells in culture: acetylated and oxidized
biotransformation products have been recovered. In contrast,
prostate-derived tumour cells that possess intrinsic resistance to
these compounds show no net benzothiazole loss from
surrounding medium and only negligible acetylation (Chua et al,
manuscript in preparation).
Double substitution at position 3 and 5 of the phenyl ring with
chlorine or bromine impairs biological activity. A similar conse-
quence follows introduction of a methyl group at position 6 of the
benzothiazole ring of DF 129. It is proposed that activating
biotransformation processes may be hindered by such structural
modifications, thus reducing compound potency.
Within the human ovarian panel, the N-chloroacetylated amine
DF 180 failed to show any specificity in its profile of anti-tumour
activity (Table 1). These observations are supported by data gener-
ated from the complete NCI tumour panel of 60 human-derived
cell lines in addition to clonogenic work.
At a concentration of 10,g ml-', DF 180 inhibited colony
formation of 18 of 22 tumours by > 70%, whereas none of the 22
tumours, which included lung, melanoma, gastric and bladder cell
lines, demonstrated this level of inhibition at 10 ng ml'. Compare
these data with corresponding figures for DF 203: at 10,g ml' in
only 2 of 22 tumours was clonogenic growth inhibition > 70%;
equally at 10 ng ml', in the same two tumours only, % T/C was
< 30%. This illustrates the selectivity (in this case, the two respon-
sive tumours were of breast origin) and potency of DF 203
compared with the general toxicity elicited by DF 180.
The NCI disease-oriented strategy fordrug discovery is based on
the hypothesis that selective activity in vitro against cancer cell
lines from a specific organ may predict selective activity against
corresponding tumours in vivo. Significant anti-tumour activity of
DF 129, DF 203 (Shi et al, 1996) and DF 229 in breast xenograft
models including MCF-7 has been demonstrated. Recently potent
anti-tumour activity of 5,4'-diaminoflavone derivatives, struc-
turally related to 2-(4-aminophenyl)benzothiazoles, has been
demonstrated in MCF-7 cells in vitro and in vivo (Akama et al,
1997). We may speculate that certain pharmacological mechanisms
ofaction may be shared. Intriguingly, two human ovarian cell lines
(A2780 and OVCAR-3) were also sensitive to the growth-
inhibitory properties of5,4'-diamino-6,8,3'-trifluoroflavone.
Specificity extended to in vivo tests. The two ovarian cell lines
routinely selected for implantation after culture in PVDF hollow
fibres were the only cell lines whose growth was inhibited after
exposure to DF 209, DF 229 and DF 203. DF 203 was signifi-
cantly more toxic; the maximum-tolerated doses of DF 209, DF
229 and DF 180 were ten times that of DF 203. Indeed, DF 203,
which, of the 3-substituted benzothiazoles, was the least powerful
inhibitor ofgrowth in vitro, proved the most effective agent tested
in retarding the growth of OVCAR-3 and OVCAR-5 tumour cells
implanted both i.p. and s.c. in hollow-fibre in vivo experiments.
Evidence ofthe biphasic dose response observed in in vitro assays
was marked in i.p. transplanted OVCAR-3 tumours exposed to DF
229 (Table 3). DF 180, as in vitro data would predict, failed to
demonstrate selectivity.
The growth delay encountered after treatment of s.c. OVCAR-3
xenograft tumours with DF 203 was not significant. Delivery via
the i.p. route may inefficiently reach s.c. sites. In support of this
theory, growth inhibition of cells cultured in hollow fibres and
implanted i.p. exceeded anti-tumour activity at s.c. sites, after
exposure to DF 209 and DF 229. The inverse relationship
observed between DF 203 concentration and % T/C appears to
reflect in vitro observations. Metabolic routes of anti-tumour
benzothiazoles in vivo and in vitro are being investigated.
Finally, the promising anti-tumour potential of these novel
benzothiazole molecules, ease of syntheses (Stevens et al 1995;
Shi et al, 1996), high yields, simple structures and compound
stability appear tojustify further preclinical development.
ABBREVIATIONS
NCI, National Cancer Institute; MTT, 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide; GI50, GI70 and GI90 concen-
trations at which 50%, 70% and 90% inhibition were encountered.
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